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Dystroglycan (DG) is an extracellular receptor composed of two subunits, a-DG and b-DG,
connected through the a-DG C-terminal domain and the b-DG N-terminal domain. We report an
alanine scanning of all DG cysteine residues performed on DG-GFP constructs overexpressed in
293-Ebna cells, demonstrating that Cys-669 and Cys-713, both located within the b-DG
N-terminal domain, are key residues for the DG precursor cleavage and trafﬁcking, but not
for the interaction between the two DG subunits. In addition, we have used immunprecipitation
and confocal microscopy showing that ERp57, a member of the disulﬁde isomerase family
involved in glycoprotein folding, is associated and colocalizes immunohistochemically with b-
DG in the ER and at the plasma membrane of 293-Ebna cells. The b-DG–ERp57 complex also
included a-DG. DG mutants, unable to undergo the precursor cleavage, were still associated to
ERp57. b-DG and ERp57 were also co-immunoprecipitated in rat heart and kidney tissues. In
vitro, a mutant ERp57, mimicking the reduced form of the wild-type protein, interacts directly
with the recombinant N-terminal domain of both a-DG and b-DG with apparent dissociation
constant values in the micromolar range. ERp57 is likely to be involved in the DG processing/
maturation pathway, but its association to the mature DG complex might also suggest some
further functional role that needs to be investigated.
& 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Dystroglycan (DG) is a member of the glycoprotein complex
associated to dystrophin and it is encoded by a single gene that is
translated in a single polypeptide chain of about 895 aminodystroglycan precursor; N
.it (M. Bozzi).
C BY-NC-ND license.acids. This precursor is cleaved into two subunits: a-DG, a highly
glycosylated peripheral membrane protein, and b-DG, a trans-
membrane protein. The two subunits are connected through the
C-terminal domain of a-DG and the N-terminal extracellular
domain of b-DG, establishing non-covalent interactions. a-DG isEM, N-ethylmaleimide; DTT, dithiothreitol; sWGL, succinylated
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 2 4 6 0 – 2 4 6 9 2461composed of two globular domains, N- and C-terminal, joined by
a central elongated mucin-like domain (rich in proline, serine
and threonine) extensively O-glycosylated and essential for the
interaction with other extracellular matrix proteins, such as
laminin, perlecan, agrin and neurexins. b-DG crosses the mem-
brane and inside the cell interacts with dystrophin, Grb-2 and
caveolin-3 among others [1,2].
The post-translational events leading to mature DG are still
largely unknown, although defects of DG processing are strictly
related to severe congenital muscular dystrophies. For example,
genetic defects linked to the eight known or putative glycosyl-
transferases responsible for the O-glycosylation of a-DG are
related to several forms of congenital muscular dystrophy also
called dystroglycanopathies [3]. Aside from the O-glycosylation
sites, a-DG primary sequence also contains some conserved sites
for N-linked glycosylation [4,5]. Although inhibition of the N-
linked glycosylation with tunicamycin generates an aberrant
targeting of a- and b-DG subunits to the plasma membrane, its
blockage does not prevent the cleavage of the DG precursor
peptide [6]; on the other hand, mutations hitting the two N-
linked glycosylation sites, located within the region containing
the Gly–Ser cleavage site, inhibit the proteolytic processing of the
precursor [7]. The amino acid region surrounding the DG
precursor cleavage site revealed sequence similarity to proteo-
lytic cleavage sites for some proteins containing SEA-modules
[7]. It has been proposed that the separation between the two DG
subunits occurs through an autocatalytic cleavage within the
SEA-module, which is stabilized by a disulﬁde bridge between
Cys-669 and Cys-713 [8]; however the functional signiﬁcance of
the DG cleavage remains obscure [9]. Our previous work showed
that site-speciﬁc mutations hitting the amino acids responsible
for the interaction between the a-DG C-terminal domain and the
b-DG ectodomain in vitro hamper the proteolytic processing of
the precursor in a DG construct tagged with GFP and over-
expressed in 293-Ebna cells [10,11]. Similar results have been
obtained by other authors mutating the two cysteine residues
belonging to the b-DG ectodomain, suggesting the presence of a
disulﬁde bridge [12].
In the present paper, an alanine scanning involving all the DG
cysteine residues has been carried out in order to achieve a
deeper insight on the redox state of the thiol groups of DG. We
also evidenced an interaction between DG and ERp57/PDIA3, a
member of the protein disulﬁde isomerase family, both in vitro
and in vivo. ERp57 is able to catalyze disulﬁde bridge oxidation or
isomerisation of non-native disulﬁde bridges and it is localized
mainly in the endoplasmic reticulum, where it speciﬁcally binds
to glycoproteins addressed to the secretory pathway during their
folding [13]. Many extracellular matrix proteins have been
identiﬁed as ERp57 substrates, such as integrins, laminins and
agrin amongst others [14]. Although ERp57 is mainly involved in
its role of chaperone for quality control in the endoplasmic
reticulum, it has also been found in other cellular compartments
where it fulﬁls a variety of other functions [15]. For example,
ERp57 has been found in the cytosol, where it participates to a
multiprotein complex responsible for the activation of the
transcription factor STAT3 [16], and in the nucleus, where
ERp57 is associated to DNA in a complex with the transcription
factor STAT3 [17,18]. Recently, a function of rapid response
receptor of vitamin D has been attributed to ERp57, suggesting
its involvement in signal transduction [19].Material and methods
Antibodies
The monoclonal antibody anti-calnexin was purchased from BD
Transduction Laboratories, the monoclonal antibody speciﬁc for
the C-terminus of b-DG(43DAG) from Novocastra (Newcastle,
UK), and the anti-GFP agarose beads and anti-GFP-HRP from
Miltenyi Biotec (Germany). The anti-ERp57 antibody was pre-
pared by immunizing rabbits with the human recombinant
protein and by a partial puriﬁcation on immobilized protein G
(Sigma), as previously reported [20].
DNA manipulation
The full-length cDNA encoding for murine DG was used as a
template to generate three DNA constructs by PCR, correspond-
ing to the N-terminal region of b-DG, b-DG(654–750), the N-
terminal region of a-DG, a-DG(30–315), and the C-terminal
region of a-DG, a-DG(485–630). Appropriate primers were used
to amplify the DNA sequences of interest. Single point mutations
were introduced into the murine DG gene, cloned in pEGFP vector,
using QuikChange site-directed mutagenesis kit (Stratagenes); all
DNA constructs were veriﬁed by automated sequencing.
The full-length DNA constructs carrying the point-mutations
were also used as templates to generate by PCR the DNA
constructs needed for the expression of b-DG(654–750) mutants
in E. coli (see below), using the same primers employed to
amplify the wild-type b-DG(654–750) sequence.
The full-length cDNA encoding for murine DG was used as a
template to generate by the gene splicing by overlap extension
technique (GENE SOEing) two overlapping DNA constructs,
which allowed, by a third PCR reaction, to insert the c-myc
epitope upon the triplet encoding for K500 [21].
Human ERp57, devoid of the 24 amino acids N-terminal
presequence, was cloned into pET21 plasmid and expressed in
E. coli BL21 [17]. To generate a functional mutant protein, the
second cysteine residue in each thioredoxin-like redox active site
of ERp57 (Cys-57 and Cys-406) was replaced with a serine one by
site-directed mutagenesis. ERp57-Cys57Ser and ERp57-Cys406-
Ser mutants were generated by PCR overlap extension using
appropriate primers. Introduced mutations were conﬁrmed by
automated sequencing. Single mutant sequences were cloned
into the pET21 vector and combined in the same sequence using
EcoRV, which cuts either between the two redox sites of the
ERp57 sequence and once within the pET21 plasmid. pET21-
ERp57-Cys57Ser and pET21-ERp57-Cys406Ser were digested
with EcoRV and the DNA fragments obtained were puriﬁed and
joined to generate the ERp57-Cys57Ser–Cys406Ser double
mutant (mutated ERp57).
Protein expression, puriﬁcation and biotinylation
The DNA constructs encoding for DG recombinant domains were
cloned into a bacterial vector, which is appropriate to express the
protein as a thioredoxin fusion product, also containing an N-
terminal 6His tag and a thrombin cleavage site. The recombinant
fusion proteins were expressed in E. coli BL21(DE3) Codon Plus
RIL strain and puriﬁed using nickel afﬁnity chromatography. The
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Tricine/SDS-PAGE was used to check the purity of the recombi-
nant proteins under analysis.
The recombinant wild-type and mutant ERp57 were puriﬁed
by ammonium sulfate fractionation, followed by chromatogra-
phy steps using the same procedure previously described for the
puriﬁcation of pig liver protein [17,22].
For solid-phase binding assays, recombinant b-DG(654–750)
and a-DG(30–315) were biotinylated in 5 mM sodium phosphate
buffer at pH 7.4, with 0.5 mg ml1 sulfo-N-hydroxylsuccinimido-
biotin (S-NHS-biotin, Pierces). The reaction mixture was incu-
bated for 30 min on ice and in the dark and then dialyzed
overnight against PBS buffer (2.5 mM KCl, 2 mM KH2PO4, 2 mM
Na2HPO4, 140 mM NaCl, pH 7.4). The optimal dilution for signal
detection was determined by dot blot analysis and revealed by
enhanced chemioluminescence (Pierces).Solid-phase binding assays
To assess the binding properties of recombinant ERp57 and its
mutant to biotinylated recombinant b-DG(654–750) and a-
DG(30–315), and the binding properties of recombinant a-
DG(485–630) to biotinylated wild-type and mutant b-
DG(654–750), solid-phase binding assays were performed as
follows: E0.5 mg of ERp57 (or a-DG(485–630)), its mutant and
BSA were immobilized on microtiter plates in coating buffer
(50 mM NaHCO3 pH 9.6) overnight at 4 1C. After washing with
PBS buffer containing 0.05% (v/v) Tween-20, 1.25 mM CaCl2 and
1 mM MgCl2, the wells were incubated with decreasing concen-
trations of recombinant biotinylated b-DG(654–750) (or a-
DG(30–315)) in PBS containing 0.05% (v/v) Tween-20, 3% (w/v)
BSA, 1.25 mM CaCl2 and 1 mM MgCl2 for 3 h at room tempera-
ture. After washing, the biotinylated bound protein fractions
were detected with alkaline phosphatase Vectastain AB Complex
(Vector Laboratoriess). 5 mg of p-nitrophenyl phosphate dis-
solved in 10 ml of 10 mM diethanolamine and 0.5 M MgCl2 were
used as a substrate for the reaction with alkaline phosphatase.
100 ml of this solution was added to all wells and absorbance
values were recorded at 405 nm. For each ligand concentration,
the absorbance value (Ai) originating from coated BSA, was
subtracted from the values obtained with coated proteins under
analysis.Cell culture, transfection and protein extraction
293-Ebna cells were grown in DMEM supplemented with anti-
biotics and 10% (v/v) fetal calf serum. Cells were transfected with
20 mg of wild-type or mutated pEGFPDG using the calcium-
phospate method: brieﬂy, DNA was mixed with 125 mM CaCl2
and 50 mM BES (BES buffered saline) and the DNA–calcium
phosphate complex was added to the cells. After 24 h cells were
treated with 25 mM N-ethylmaleimide (NEM) to preserve mixed
disulﬁdes, and lysed in PBS containing 1% Triton X-100, 20 mM
NEM and protease inhibitors and centrifuged at 14,000 rpm for
10 min at 4 1C. Cell lysates were subjected either to immuno-
precipitation or WGL-enrichment assay and Western blot
analysis.Immunoprecipitation
Equal amounts of total protein extracts from homogenized
tissues or from untransfected cells or overexpressing wild-type
or mutated DG-GFP constructs were precleared with protein A/G-
Sepharose beads (GE Healthcare) at 4 1C for 1 h. Supernatants
were immunoprecipitated for 2 h at 4 1C with a speciﬁc antibody
or with a non related antibody as negative control. The
protein–antibody complexes were pulled down by adding pro-
tein A/G-Sepharose beads. Sample pellets were then subjected to
several washes in PBS. The immunocomplexes were recovered
from the protein A/G-Sepharose beads by boiling the samples in
electrophoresis loading buffer. Alternatively, cell lysates were
immonoprecipitated with anti-GFP conjugated to magnetic beads
(Miltenyi) following manufacture’s instructions. One percent of
total protein extracts used for immunoprecipitation was loaded
as input. The immunocomplexes were analyzed by Western blot.
WGL-enrichment assay
Total protein extracts from untransfected cells or overexpressing
wild-type or mutated DG-GFP constructs were incubated with
succinylated Wheat Germ Lectin (sWGL) Sepharose 6 MB (Amer-
sham) and equilibrated in PBS containing 1% Triton X-100 over-
night at 4 1C. After extensive washing with washing buffer (WB)
(50 mM Tris–HCl pH 7.8, 500 mM NaCl, 0.1% Triton X-100),
bound glycoproteins were eluted in WB containing 300 mM N-
acetylglucosamine and analyzed in Western blot.
Electrophoresis and Western blot analysis
Samples for SDS-PAGE were resuspended in SDS-PAGE sample
buffer and 50 mM dithiothreitol (DTT) was added to reduce
samples where indicated. All samples were boiled for 5 min
before electrophoresis. Proteins were resolved on SDS-PAGE and
transferred to nitrocellulose membranes for Western blot analy-
sis. Membranes were extensively blocked with 3% milk in PBS
containing 0.5% (v/v) Tween-20 (TPBS). Primary antibody incu-
bations were performed overnight at 4 1C in TPBS containing 3%
(w/v) BSA, whereas secondary antibodies (polyclonal goat anti-
rabbit, UCS Diagnostics, Italy (1:10000), or monoclonal goat
anti-mouse, GenScript Corp s (1:5000), immunoglobulins con-
jugated to horseradish peroxidase), were diluted in TPBS contain-
ing 3% (w/v) BSA at room temperature for 1 h. The reactive
products were revealed using the luminol-based ECL system
(Pierces, USA). Every experiment has been repeated at least
three times.
High-resolution ﬂuorescence microscopy
Transiently transfected 293-Ebna cells were ﬁxed and permea-
bilized in PBS containing 1% Triton X-100 at room temperature
for 20 min followed by incubation with the anti-ERp57 antibody
(1:50) in PBS containing 0.1% Triton X-100 and 3% BSA for 1 h.
After several washes the cells were incubated with anti-rabbit
Alexa Fluor633 secondary antibody (Invitrogen) (1:500), imaged
with a confocal laser scanning system (TCS-SP2, Leica Micro-
systems, GmbH, Wetzlar, Germany) and analyzed with ImageJ
programs (http://rsbweb.nih.gov/ij/). Laser excitation at 488 nm
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emission signals from GFP and Alexa Fluor633, respectively.Results and discussion
Effect of DG cysteine replacement on the DG precursor
cleavage
Previous studies carried out in vitro on the recombinant a-DG N-
terminal domain indicated the presence of a disulﬁde bridge
between the cysteines Cys-182 and Cys-264, whose disruption
dramatically reduced the structural stability of the domain [23].
More recent studies carried out on eukaryotic cells proposed the
presence of a disulﬁde bridge within the b-DG N-terminal
domain between the cysteines Cys-669 and Cys-713, which
would also represent a structural determinant for the a-DG/b-
DG interface [12].
Six DG-GFP constructs were prepared carrying single point
mutations in which every DG cysteine was replaced with alanine
and used to transiently transfect 293-Ebna cells in order to
analyze the effects of such mutations (Fig. 1A). Lysates from 293-
Ebna cells overexpressing the mutated DG-GFP constructs were
run through an SDS-PAGE, transferred to nitrocellulose and
probed with 43DAG, a monoclonal antibody directed against
the C-terminus of b-DG, which detected a main band at 60 kDa,
corresponding to b-DG-GFP, and a lower band at about 50 kDa
due to some N-terminal degradation. Fig. 1(B) shows that the
Cys182Ala, Cys264Ala, Cys642Ala and Cys774Ala mutants under-
went a correct DG precursor cleavage, whereas the Cys669Ala
and Cys713Ala mutations partially hindered the separation
between the two DG subunits, as suggested by the presence ofFig. 1 – Mutations Cys669Ala and Cys713Ala partially hamper th
complex. Numbers on the top refer to the amino acid positions of
the cysteines Cys-182 and Cys-264 and the cysteines Cys-669 and
transmembrane region. (B) Lysates from 293-Ebna cells transfect
transferred to nitrocellulose and probed with a monoclonal antibo
mutants carrying the point mutations Cys182Ala, Cys264Ala, Cys6
corresponding to the cleaved b-DG-GFP. A lower band, at about 50
The Cys669Ala and Cys713Ala DG-GFP mutants showed a higher b
the unprocessed DG precursor, pre-DG, displayed by the Ser654Ala
cleaved b-DG-GFP, devoid of its N-terminus. Asterisk marks unspea high molecular weight band of about 160 kDa. In fact, this band
has the same electrophoretic mobility displayed by the one
occurring with the Ser654Ala mutation, located at the physiolo-
gical a/b maturation cleavage site Gly653–Ser654, that comple-
tely hampers the DG precursor cleavage (Fig. 1B) [7,8,11,24].
The band corresponding to the cleaved b-DG-GFP, detected
with the Cys669Ala and Cys713Ala mutants, showed a faster
electrophoretic mobility than the one displayed by all the other
constructs, probably due to some further N-terminal
degradation.Effect of Cys669Ala and Cys713Ala mutations on the a-DG/
b-DG interaction in vitro
It is known that the two DG subunits form a noncovalent
complex involving the C-terminal domain of a-DG and the
N-terminal extracellular domain of b-DG [25]. Mass spectro-
metry experiments revealed that the two cysteine residues, Cys-
669 and Cys-713, do not form a disulﬁde bridge within the
recombinant N-terminal extracellular domain of b-DG, b-
DG(654–750), expressed in E. coli (data not shown). Nevertheless,
in our previous work [10,11,25], we have demonstrated that b-
DG(654–750) still interacts with the C-terminal domain of a-DG.
In order to evaluate the involvement of the two single cysteines
in the a-DG/b-DG interface, two b-DG(654–750) mutants, carry-
ing the two amino acid substitutions Cys669Ala and Cys713Ala,
were prepared and their afﬁnity toward the recombinant a-DG
C-terminal domain, a-DG(485–630), was tested by solid-phase
binding assays. Fig. 2 shows that the afﬁnity of the two mutated
domains, used as biotinylated soluble ligands, toward the
recombinant a-DG(485–630), coated onto microtiter plates,e DG precursor cleavage. (A) Schematic representation of DG
cysteine residues. The two putative disulﬁde bridges between
Cys-713 are also reported. SP, signal peptide, TM,
ed with DG-GFP mutants were resolved on SDS-PAGE,
dy directed against the b-DG C-terminus (43DAG). The DG-GFP
42Ala and Cys774Ala displayed a band at about 60 kDa
kDa, probably originated from further proteolysis of b-DG-GFP.
and at 160 kDa (black arrow), which is likely to correspond to
mutant. The two other lower bands were probably due to the
ciﬁc bands.
Fig. 2 – Mutations Cys669Ala and Cys713Ala do not hinder the
interaction between the a-DG C-terminal domain and the b-
DG N-terminal domain in solid-phase binding assays.
a-DG(485–630) was immobilized on plate, whereas
b-DG(654–750) (full circles) and its mutants, b-DG(654–750)
Cys669Ala (open circles) and b-DG(654–750) Cys713Ala (open
squares), were used as biotinylated ligands. Each continuous
line corresponds to a representative experiment (from a set of
at least three experiments with similar results) and was
obtained by ﬁtting experimental data to a single class of
equivalent binding sites equation.
Fig. 3 – Western blot of sWGL enriched wild-type and mutated
DG-GFP constructs. Wild-type or mutated DG-GFP constructs,
overexpressed in 293-Ebna cells, were enriched with sWGL
conjugated to agarose beads. sWGL speciﬁcally binds to the N-
acetylglucosamine moieties covalently linked to the core
protein of a-DG. Beads can retain also b-DG-GFP, as it is
associated to a-DG through non-covalent interactions, or
directly pre-DG. Total protein extracts and protein fractions
eluted from sWGL conjugated beads were resolved on SDS-
PAGE, transferred to nitrocellulose and probed with 43DAG.
Testing wild-type and all mutated DG-GFP constructs, b-DG-
GFP was retained by the beads as well as pre-DGs originating
from the Cys669Ala and Cys713Ala mutants, in which the
cleavage is partially hampered. The cleaved b-DG-GFP
originated by these two mutants could not be retained by the
sWGL. Tot, total protein extracts, E, protein fractions eluted
from sWGL.
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DG(654–750). The mean values of the apparent dissociation
constants KD measured were in the micromolar range
(470.9 mM for Cys669Ala, 671 mM for Cys713Ala and
370.8 mM for wild-type). This indicates that the two cysteine
residues are dispensable for the correct formation of the a-DG/b-
DG interface. In contrast with the conclusions of Watanabe and
colleagues [12], it can be argued that the inhibition of the DG
precursor cleavage, observed with the Cys669Ala and Cys713Ala
mutants in transfected eukaryotic cells, is not due to a dramatic
impairment of the a-DG/b-DG interface within the DG precursor,
but it is likely due to the speciﬁc destabilization of a proposed
SEA-module, which encompasses the DG precursor cleavage site
(a.a. 653–654) and that would be possibly stabilized by the
disulﬁde bridge between Cys-669 and Cys-713 [7,8].
Effect of DG cysteine replacement on the a-DG
glycosylation
a-DGXb-DG complex can be enriched from eukaryotic cell
lysates with wheat germ lectin conjugated to agarose beads.
Succinylated wheat germ lectin (sWGL) speciﬁcally binds the N-
acetylglucosamine moieties covalently linked to the a-DG core
protein. As b-DG is associated to a-DG through non-covalent
interactions, it can be retained from the beads. In order to verify
if the mutations hitting the cysteine residues perturb the inter-
action between a-DG and b-DG and if they alter a-DG decoration
with N-acetylglucosamine residues, each of the six DG-GFP
constructs, mutated in a single cysteine residue, was over-
expressed in 293-Ebna cells, enriched with sWGL conjugated to
agarose beads and analyzed by Western blot. The data obtained
indicate that DG cysteine replacement does not alter the a-DG
glycosylation pattern. Fig. 3 shows that b-DG-GFP, but not its
degradation product, can be detected in sWGL pulled downproteins with the Cys182Ala, Cys264Ala, Cys642Ala and
Cys774Ala mutations, demonstrating that a-DG was processed,
correctly decorated with N-acetylglucosamine residues and
bound to b-DG-GFP. The DG precursors (pre-DGs) obtained with
the Cys669Ala and Cys713Ala mutations were pulled down by
sWGL, indicating that they are at least partially decorated with
N-acetylglucosamine moieties, in accordance with the results
obtained with the Ser654Ala mutant and with other DG con-
structs, carrying mutations hitting the amino acids responsible
for the interaction between the two DG subunits and unable to
undergo the precursor cleavage [11]. The cleaved b-DG-GFP
generated by the Cys669Ala and Cys713Ala mutants, probably
devoid of its N-terminus, lost contact with a-DG and was not
retained by the sWGL (Fig. 3).Confocal ﬂuorescence microscopy analysis of cysteine
mutated DG-GFP constructs
Confocal ﬂuorescence microscopy analysis of 293-Ebna cells
overexpressing mutated DG-GFP constructs evidenced that pre-
DGs carrying the Cys669Ala and Cys713Ala single point muta-
tions were trapped within ER/Golgi, whereas the Cys182Ala,
Cys642Ala and Cys774Ala mutations did not perturb the trafﬁck-
ing neither the membrane localization of the corresponding b-
DG-GFP constructs. The Cys264Ala mutant, although still loca-
lized at the plasma membrane, showed a more patchy and
diffuse cytosolic signal (see Fig. 1 of supplementary data).
Differently from the b-DG disulﬁde bridge, disruption of the
putative a-DG disulﬁde bridge had no tremendous effects on
b-DG trafﬁcking and on its membrane localization. This could be
explained considering that the folding of a-DG N-terminal
domain is largely autonomous [26].
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disulﬁde isomerase family, as a DG associated protein in
eukaryotic cells and in rat heart and kidney tissues
We wondered if the formation of the two putative disulﬁde
bridges, within the a-DG N-terminal domain (between Cys-182
and Cys-264) and the b-DG ectodomain (between Cys-669 and
Cys-713), may represent a step assisted by a chaperone in
eukaryotic cells. Since ERp57/PDIA3 is one of the most popular
ER-associated molecular chaperones with oxido-reductase activ-
ity that assists many glycoproteins to achieve their ﬁnal con-
formation, we explored the possibility that ERp57 may be
involved in DG precursor processing and maturation. To this
aim, 293-Ebna cells were transfected with a wild-type DG-GFP
construct or with the expression vector containing only the GFP
construct as control. Before lysis, intact cells were treated with
the membrane permeable alkylating agent N-ethylmaleimide
(NEM) to prevent disulﬁde exchange and to reveal possible
mixed disulﬁdes between DG-GFP and ERp57. Cell lysates were
immunopuriﬁed with an anti-GFP antibody conjugated to mag-
netic beads. Proteins eluted from the beads were resolved on
SDS-PAGE under reducing and non-reducing conditions and
transferred to nitrocellulose membranes. Western blot analysisFig. 4 – ERp57 was co-immunopuriﬁed with b-DG-GFP. (A) Lysates f
subjected to immunopuriﬁcation with anti-GFP and immunoblotte
with anti-ERp57 and anti-calnexin after stripping of the same nit
immunoblotted with anti-GFP. Anti-ERp57 detected three bands a
GFP detected GFP alone at about 20 kDa and b-DG-GFP at about 6
overexpressing DG-GFP, or from rat kidney and heart extracts we
immunoblotted with anti-GFP-HRP, 43DAG and with anti-calnexi
293-Ebna cells, transfected with a wild-type DG-GFP construct or w
to immunopuriﬁcation with anti-myc and immunoblotted with a
untransfected or overexpressing wild-type DG-GFP, were sWGL en
ERp57 and immunoblotted with anti-GFP-HRP or 43DAG. Tot, tot
anti-myc or anti-ERp57, eDG, endogenous dystroglycan, sWGL, suwas carried out with an afﬁnity puriﬁed rabbit polyclonal anti-
body directed against human ERp57 (anti-ERp57). As shown in
Fig. 4(A), anti-GFP co-immunoprecipitated ERp57, which dis-
played three bands at about 60 kDa, probably related to protein
isoforms or modiﬁcations, beside a band with a lower molecular
mass most likely an ERp57 degradation product. Anti-GFP failed
to precipitate ERp57 from 293-Ebna cells overexpressing GFP
alone, demonstrating the speciﬁcity of the interaction between
DG and ERp57. No bands could be detected at higher molecular
mass and corresponding to mixed disulﬁde products between b-
DG-GFP and ERp57, thus indicating a non-covalent association.
Similarly, anti-ERp57 co-immunoprecipitated b-DG-GFP, as can
be observed by Western blot analysis with an anti-GFP antibody
conjugated with horseradish peroxidase and with 43DAG
(Fig. 4B). To exclude the possibility that the association between
b-DG and ERp57 was the result of DG-GFP overexpression in
293-Ebna cells, untransfected 293-Ebna cell lysates were immu-
noprecipitated with anti-ERp57 and immunoblotted with
43DAG. The presence of a speciﬁc band in the immunoprecipi-
tated sample demonstrated that the interaction between ERp57
and b-DG was not induced by DG-GFP overexpression (Fig. 4B).
Endogenous b-DG was co-immunoprecipitated by anti-ERp57
also in rat tissue extracts, such as heart and kidney, where arom 293-Ebna cells, overexpressing GFP alone or DG-GFP, were
d under reducing (þDTT) and non-reducing (DTT) conditions
rocellulose. 20% of the immunopuriﬁed fractions were
t about 60 kDa related to three ERp57 isoforms, whereas anti-
0 kDa. (B) Lysates from 293-Ebna cells, untransfected or
re subjected to immunopuriﬁcation with anti-ERp57 and
n after stripping of the same nitrocellulose. (C) Lysates from
ith a myc tagged DG-GFP-K500-myc construct, were subjected
nti-ERp57 and 43DAG. (D) Lysates from 293-Ebna cells,
riched and then subjected to immunopuriﬁcation with anti-
al protein extracts, E, protein fractions eluted from anti-GFP,
ccinylated wheat germ lectin enriched protein fraction.
Fig. 5 – Effect of the DG-GFP cysteine replacement on the DG-
GFP/ERp57 interaction. 293-Ebna cells, overexpressing wild-
type or mutated DG-GFP constructs, carrying the mutations
Cys182Ala, Cys264Ala, Cys642Ala, Cys669Ala, Cys713Ala,
Cys669Ala–Cys713Ala and Cys774Ala (A) and
Cys264Ala–Cys669Ala (B), were treated with NEM before lysis.
b-DG-GFP constructs were immunopuriﬁed with anti-GFP
conjugated to magnetic beads. Protein fractions eluted from
the beads were resolved on SDS-PAGE under reducing (þDTT)
or non-reducing (–DTT) conditions, transferred to
nitrocellulose, and probed with anti-ERp57 or 43DAG. Tot,
total protein extracts, E, protein fractions eluted from anti-
GFP conjugated to magnetic beads.
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with 43DAG (Fig. 4B).
Since the lectin calnexin is often associated to ERp57 to assist
the folding of its targets [27], we tested the presence of calnexin
in the immunoprecipitates. Nitrocellulose membranes of the
previous Western blot experiments were stripped and incubated
with an anti-calnexin antibody, which failed to detect calnexin in
the immunoprecipitated samples (Fig. 4A and B).
There are not available antibodies directed against a-DG
expressed in 293-Ebna cells. In order to verify the presence of
a-DG in the b-DG-GFP/ERp57 protein complex, a DG-GFP con-
struct was expressed, in which a 10 amino acids myc-tag was
inserted before the Ig-like domain of the a-DG C-terminal
portion, at the amino acid position 500 [28]. The DG-GFP-
K500-myc construct was immunopuriﬁed with an anti-myc
antibody conjugated to magnetic beads and immunoblotted with
rabbit anti-ERp57 and 43DAG, demonstrating the presence of a-
DG in the b-DG-GFP/ERp57 protein complex. Co-immunopreci-
pitated ERp57 displayed a different mobility compared to protein
detected in the whole extract and this could be related to the
enrichment of a speciﬁc protein isoform or modiﬁcation, as
above observed in Fig. 4(A). As control, ERp57 was not detected
in the anti-myc immunopuriﬁed fractions from cells overexpres-
sing DG-GFP, demonstrating the speciﬁcity of the antibodies
utilized (Fig. 4C). The presence of a-DG in the b-DG-GFP/ERp57
complex was conﬁrmed using sWGL, which speciﬁcally binds a-
DG, to enrich the DG complex, and then anti-ERp57 to co-
immunoprecipitate sWGL enriched b-DG-GFP or endogenous b-
DG (Fig. 4D).
Effect of DG cysteine replacement on DG association to
ERp57
In order to determine whether ERp57 is still associated to the
mutated DG-GFP constructs, they were overexpressed in 293-
Ebna cells and immunopuriﬁed with an anti-GFP antibody
conjugated to magnetic beads. The eluted proteins were resolved
on SDS-PAGE under reducing and non-reducing conditions and
transferred to nitrocellulose membrane to detect ERp57 with
anti-ERp57. The bands at about 60 kDa referring to ERp57 could
be observed with all the mutants tested, indicating that none of
the DG cysteine residues appears to be speciﬁcally responsible
for the ERp57/DG association (Fig. 5A). Besides ERp57, an
additional unidentiﬁed band of about 160 kDa was detected with
the Cys669Ala and Cys713Ala mutants, either under non-redu-
cing or reducing conditions (Fig. 5A). To rule out the possibility
that the 160 kDa component was the result of a mixed disulﬁde
between ERp57 and b-DG-GFP, resistant to a strong reducing
treatment, we prepared a DG-GFP construct carrying the
Cys669Ala–Cys713Ala double mutation. This was immunopur-
iﬁed with anti-GFP and analyzed by Western blot performed
with anti-ERp57, under reducing and non-reducing conditions.
Fig. 5(A) shows that the signal at 160 kDa could be detected also
with the Cys669Ala–Cys713Ala double mutant. At present we
cannot attribute the 160 kDa band to any speciﬁc cellular
product, but it may be hypothesized that the Cys669Ala and
Cys713Ala mutants, which are blocked within the ER/Golgi
compartment (see Fig. 1 of supplementary data) form some sort
of covalent complexes with the chaperone ERp57. In order to
disrupt together the two putative disulﬁde bridges,Cys182–Cys264 and Cys669–Cys713, located within the a-DG
and b-DG N-terminal domains, respectively, a DG-GFP construct,
carrying the Cys264Ala–Cys669Ala double mutation, was pre-
pared and overexpressed in 293-Ebna cells, immunopuriﬁed with
anti-GFP antibody conjugated to magnetic beads and immuno-
blotted with anti-ERp57. About 20% of the immunopuriﬁed
protein fraction was immunoblotted with 43DAG. Interestingly,
the 60 kDa bands related to ERp57 were lost under both,
reducing and non-reducing conditions (Fig. 5B). This may suggest
that at least one of the two potential disulﬁde bridges of DG must
be maintained for DG to interact with ERp57. Curiously, the same
unidentiﬁed band at 160 kDa, previously observed, was also
visible in the immunoprecipitate of Cys264Ala-Cys669Ala double
mutant, conﬁrming that this occurrence is related to the impair-
ment of DG processing.
DG and ERp57 co-localize within 293-Ebna cells
Confocal ﬂuorescence microscopy, performed on 293-Ebna cells
transiently transfected with wild-type DG-GFP and carrying
the Cys264Ala–Cys669Ala double mutation, showed that both,
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plasma membrane, and the Cys264Ala–Cys669Ala mutant, which
is retained within ER/Golgi compartments, co-localized with
endogenous ERp57 in discrete patches throughout the cells
suggesting a possible association of the two proteins both, within
ER compartment and at the plasma membrane (see Fig. 2 of
supplementary data).The recombinant a-DG and b-DG N-terminal domains bind
only the reduced form of ERp57
ERp57 is formed by four thioredoxin-like domains with the N-
and C-terminal domains containing the catalytic CXXC motifs
[29]. The N-terminal cysteine within these motifs forms a mixed
disulﬁde with substrates, and the C-terminal cysteine of the
motif subsequently attacks the intermolecular disulﬁde bond,
leading to the release of substrate and to the oxidation of the
catalytic motif [30]. An ERp57 double mutant, in which the C-
terminal cysteine of both catalytic sites was replaced with a
serine, simulates the reduced form of the protein. In order to
verify a direct interaction between ERp57 and the DG domains
containing the putative disulﬁde bridges, solid-phase bindingFig. 6 – Mutated ERp57 binds the N-terminal domains of a-DG
and b-DG in solid-phase binding assay. Recombinant wild-
type (open circles) and mutated (full circles) ERp57 were
immobilized on plate and tested for the binding towards
soluble biotinylated a-DG(30–315) (A) and b-DG(654–750) (B).
Each continuous line corresponds to a representative
experiment (from a set of at least three experiments
producing similar results) and was obtained by ﬁtting
experimental data to a single class of equivalent binding sites
equation.assays were carried out coating onto a microtiter plate the
recombinant ERp57 and its double mutant and using biotinylated
recombinant N-terminal domains of both, a-DG and b-DG, as
soluble ligands at increasing concentrations (up to 20 mM). Fig. 6
shows that neither a-DG nor b-DG N-terminal domains dis-
played signiﬁcant afﬁnity toward wild-type ERp57, whereas they
bound to the double mutant with an apparent dissociation
constant in the micromolar range (370.9 mM for a-DG(30–315)
and 1070.9 mM for b-DG(654–750)). This suggests the existence
of a direct non-covalent interaction between DG and ERp57,
which depends on the redox state of ERp57. It should be noted
that the apparent dissociation constant values measured are fully
comparable with the ones measured for the binding between b-
DG(654–750) and the a-DG C-terminal domain, its biological
partner [10,11].Conclusions
In this paper we report for the ﬁrst time an association between
ERp57, a member of the disulﬁde isomerase family, and DG. In
the immunopuriﬁed protein fractions containing a chimaeric
protein DG-GFP and its mutants, Cys182Ala, Cys264Ala,
Cys642Ala and Cys774Ala, which are correctly separated into
two subunits, glycosylated and targeted to the plasma mem-
brane, ERp57 was detected at its expected relative molecular
mass of about 60 kDa. With the Cys669Ala and Cys713Ala
mutants, which are entrapped within the ER/Golgi compartment,
ERp57 was detected also as a high molecular mass species
probably related to stable complexes between ERp57 and pre-DG.
No species with higher molecular mass due to mixed disulﬁdes
between ERp57 and DG were detected under non-reducing condi-
tions, suggesting a non-covalent interaction between DG and ERp57.
However, there is the possibility that mixed disulﬁdes between DG
and ERp57 could not be detected because such species are too
transient to be accumulated within the cells and revealed with this
technique [31]. ERp57 did not bind to DG when it carries the
Cys264Ala–Cys669Ala double mutation, which disrupts both the
two putative disulﬁde bridges, Cys182–Cys264 and Cys669–Cys713.
It can be argued that ERp57 may assist DG during its post-
translational maturation, catalyzing the formation of the two
disulﬁde bridges.
In addition, it can be hypothesized that ERp57 is associated
also to the completely mature DG to modulate its redox state.
This is supported by two lines of evidence: the ﬁrst one refers to
the co-localization of ERp57 and wild-type DG within the ER/
Golgi compartments but also at the plasma membrane where DG
is correctly folded (Fig. 2 of supplementary data). The second one
comes from the solid-phase binding experiments reported in
Fig. 6 showing that the recombinant N-terminal domain of both,
a-DG and b-DG, binds only the recombinant ERp57 mutant
mimicking the reduced form of the protein. Recently, it has been
proposed that enzyme catalyzed reduction or reorganization of
disulﬁde bonds within surface receptors may induce conforma-
tional changes capable of modulating their activity [32,33].
Accordingly, it was hypothesized that cell-surface ERp57 regu-
lates platelet aggregation, driving integrin transition from an
inactive state to a ligand binding conformer by catalyzing the
remodeling of disulﬁde bonds within the receptor itself or other
substrates [34]. Other cell surface receptors were found to be
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 8 ( 2 0 1 2 ) 2 4 6 0 – 2 4 6 92468associated to members of the disulﬁde isomerase protein family,
such as the receptor glycoprotein GP1ba, which is associated to
PDI on platelets [35] and the integrin b3 subunit, which is
associated to ERp5 [36]. In these cases, the disulﬁde isomerases
do not assist their targets during folding, but modulate the redox
state of the completely mature protein receptors at the cell
membrane. Further experiments will be needed to test this
hypothesis.Funding
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